NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Price, News & Analysis $2.98 -0.03 (-1.00%) Closing price 04:00 PM EasternExtended Trading$3.03 +0.05 (+1.68%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Anixa Biosciences Stock (NASDAQ:ANIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Anixa Biosciences alerts:Sign Up Key Stats Today's Range$2.90▼$3.0950-Day Range$2.76▼$3.7552-Week Range$2.07▼$4.20Volume165,214 shsAverage Volume107,546 shsMarket Capitalization$95.99 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Read More Anixa Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreANIX MarketRank™: Anixa Biosciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 285th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAnixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Anixa Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -7.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -7.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 5.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Anixa Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.26% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Anixa Biosciences has recently decreased by 5.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.26% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Anixa Biosciences has recently decreased by 5.96%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.85 News SentimentAnixa Biosciences has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Anixa Biosciences this week, compared to 2 articles on an average week.Search Interest8 people have searched for ANIX on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $139,200.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders25.30% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.13% of the stock of Anixa Biosciences is held by institutions.Read more about Anixa Biosciences' insider trading history. Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIX Stock News HeadlinesAnixa Biosciences Inc (NASDAQ:ANIX) Director Acquires $30,800.00 in StockAugust 5 at 4:44 AM | insidertrades.comAnixa Biosciences Inc (NASDAQ:ANIX) CEO Buys $15,800.00 in StockAugust 1, 2025 | insidertrades.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 8 at 2:00 AM | Brownstone Research (Ad)Arnold M. Baskies Purchases 5,000 Shares of ANIXA BIOSCIENCES INC (NASDAQ:ANIX) StockJuly 22, 2025 | insidertrades.comAnixa Biosciences Inc (NASDAQ:ANIX) Director Acquires $31,400.00 in StockJuly 16, 2025 | insidertrades.comAnixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer ConferenceAugust 8 at 9:15 AM | prnewswire.comD. Boral Capital Reiterates "Buy" Rating for Anixa Biosciences (NASDAQ:ANIX)August 7 at 2:55 AM | americanbankingnews.comAnixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine TrialAugust 4, 2025 | prnewswire.comSee More Headlines ANIX Stock Analysis - Frequently Asked Questions How have ANIX shares performed this year? Anixa Biosciences' stock was trading at $2.32 at the beginning of the year. Since then, ANIX shares have increased by 28.4% and is now trading at $2.98. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences Inc (NASDAQ:ANIX) issued its earnings results on Tuesday, June, 3rd. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Who are Anixa Biosciences' major shareholders? Top institutional investors of Anixa Biosciences include Mission Wealth Management LP (1.15%). Insiders that own company stock include Lewis H Titterton Jr, Amit Kumar, Arnold M Baskies and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anixa Biosciences investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Coty (COTY), AbbVie (ABBV), Adverum Biotechnologies (ADVM) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings6/03/2025Today8/08/2025Next Earnings (Estimated)9/05/2025Fiscal Year End10/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANIX CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees5Year FoundedN/APrice Target and Rating Average Price Target for Anixa Biosciences$9.00 High Price Target$10.00 Low Price Target$7.00 Potential Upside/Downside+203.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.55 million Net MarginsN/A Pretax MarginN/A Return on Equity-68.17% Return on Assets-60.38% Debt Debt-to-Equity RatioN/A Current Ratio8.89 Quick Ratio8.89 Sales & Book Value Annual Sales$210 thousand Price / Sales454.77 Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book5.03Miscellaneous Outstanding Shares32,210,000Free Float24,062,000Market Cap$95.50 million OptionableOptionable Beta0.43 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ANIX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.